A 4-drug combination (Stribild) for HIV

Medical Letter on Drugs and Therapeutics

Volumn 54, Issue 1404, 2012, Pages 95-96

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; CYTOCHROME P450 3A INHIBITOR; CYTOCHROME P450 3A4; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; KETOCONAZOLE; MIDAZOLAM; MULTIDRUG RESISTANCE PROTEIN; RALTEGRAVIR; RIFABUTIN; RIFAMPICIN; SIMVASTATIN; TENOFOVIR DISOPROXIL; VIRUS RNA; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CARBAMIC ACID DERIVATIVE; COBICISTAT; DEOXYCYTIDINE; DRUG DERIVATIVE; ELVITEGRAVIR; PHOSPHONIC ACID DERIVATIVE; QUINOLONE DERIVATIVE; THIAZOLE DERIVATIVE;

CREATININE CLEARANCE; CROSS RESISTANCE; DIARRHEA; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG COST; FOOD AND DRUG ADMINISTRATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; KIDNEY FAILURE; NAUSEA; NONHUMAN; NOTE; PROVIRUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); VIRUS REPLICATION; ARTICLE; CLINICAL TRIAL (TOPIC); DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS; ISOLATION AND PURIFICATION; MULTIDRUG RESISTANCE; UNITED STATES; VIROLOGY;

ADENINE; ANTI-HIV AGENTS; CARBAMATES; CLINICAL TRIALS AS TOPIC; DEOXYCYTIDINE; DOUBLE-BLIND METHOD; DRUG APPROVAL; DRUG COMBINATIONS; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV; HIV INFECTIONS; HUMANS; ORGANOPHOSPHONATES; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIAZOLES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84873473068     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (6)

1. Two new drugs for HIV infection. Med Lett Drugs Ther 2008; 50:2.
2. Drugs for HIV infection. Treat Guidel Med Lett 2011; 9:29.
3. Panel of Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. March 27, 2012. Available at www.aidsinfo.nih.gov. Accessed November 14, 2012.
4. PE Sax et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012; 379:2439.
5. E DeJesus et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavirboosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 2012; 379:2429.
6. C Garrido et al. Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens. Antimicrob Agents Chemother 2012; 56:2873.